CLSTN3

CLSTN3 (calsyntenin-3) is a multifunctional transmembrane protein whose roles span synaptic organization, lipid storage, immune regulation, and systemic metabolism (PMID:24094106, PMID:36477540, PMID:41849401). At the synapse, it acts postsynaptically as a synapse-organizing protein that directly binds neurexins to trigger both excitatory and inhibitory presynapse differentiation, with its shed ectodomain conversely suppressing presynaptic induction by other organizers (PMID:24094106). The interaction is high-affinity and Ca2+-dependent, mediated by the CLSTN3 LNS and cadherin domains binding the LNS domain of neurexin, and is selective in vivo for splice-site-4 (SS4)-positive neurexins, whose expression rescues CLSTN3 synaptogenic activity; CLSTN3 cadherin domains also support homophilic cell adhesion (PMID:25352602, PMID:25463516, PMID:32434929). Loss of Clstn3 reduces synapse density and impairs synaptic transmission, and neuron-specific deletion reduces excitatory inputs (PMID:24094106, PMID:32434929). Beyond the brain, an adipocyte-selective ER-membrane isoform, CLSTN3β, localizes to ER–lipid droplet contact sites and restricts lipid droplet fusion by associating with CIDE proteins and impairing their lipid-transfer activity, enforcing a multilocular droplet phenotype required for normal brown adipose function (PMID:36477540). In macrophages, CLSTN3 suppresses innate immune activation by binding the OST subunit DDOST, blocking its interaction with the catalytic subunit STT3A and thereby reducing N-glycosylation and membrane translocation of TLR4 and other TLRs (PMID:41849401). CLSTN3 additionally interacts with the vitamin C transporter SVCT2 to promote neuronal ascorbic acid uptake, and neuronal CLSTN3 regulates systemic energy and bone homeostasis through a leptin-sensitive pathway (PMID:32382066, PMID:34673103).

1. 2013 High

   Established CLSTN3 as a bona fide postsynaptic synapse organizer, answering whether it has a direct trans-synaptic signaling role rather than a passive structural one.

   Evidence Unbiased screen with cell-based synaptogenesis assays, Co-IP, EM/confocal imaging, and electrophysiology in Clstn3-/- mice

   PMID:24094106

   Open questions at the time

   • Did not resolve the structural basis of the neurexin interaction
   • Initially reported binding only to α-neurexins, not β-neurexins
2. 2014 High

   Defined the biophysical and domain basis of CLSTN3–neurexin binding, showing it is direct, high-affinity, Ca2+-dependent, and mechanistically distinct from neuroligin.

   Evidence EM architecture, biochemical/biophysical binding assays, and mutagenesis-guided domain mapping in vitro

   PMID:25352602

   Open questions at the time

   • No atomic-resolution structure of the complex
   • Functional role of tetramerization in synapse formation not established
3. 2014 Medium

   Showed the CLSTN3 ectodomain can mediate homophilic adhesion through its cadherin repeats, addressing a possible adhesive function independent of neurexin.

   Evidence Zebrafish clstn3 cloning with bead-sorting adhesion assays and domain mapping

   PMID:25463516

   Open questions at the time

   • Single method/lab
   • No homophilic paralog preference and no in vivo relevance demonstrated
4. 2020 High

   Refined the synaptic mechanism by demonstrating CLSTN3 also binds β-neurexins with selectivity for SS4-positive variants, identifying the splice code governing complex formation.

   Evidence LC-MS/MS, RNAscope, electrophysiology, and conditional KO with cadherin-domain rescue in CA1 neurons

   PMID:32434929

   Open questions at the time

   • Differential contribution to inhibitory versus excitatory synapses not fully resolved
   • Mechanism of SS4-dependent selectivity not structurally defined
5. 2020 High

   Extended CLSTN3 function beyond synapses to systemic physiology, showing neuronal CLSTN3 controls energy expenditure, leptin sensitivity, and bone mass non-cell-autonomously.

   Evidence Global and cell-type-specific conditional KO mice with metabolic and bone-microarchitecture phenotyping

   PMID:32382066

   Open questions at the time

   • Neuronal circuit and downstream effectors linking CLSTN3 to leptin signaling unidentified
   • Molecular mechanism connecting synaptic function to bone homeostasis unknown
6. 2021 High

   Identified a transporter-regulatory role for CLSTN3, showing it binds SVCT2 and promotes neuronal vitamin C uptake.

   Evidence Y2H, Co-IP, M2H, co-localization, and ascorbic-acid uptake assays with gain/loss-of-function in human cell lines

   PMID:34673103

   Open questions at the time

   • Mechanism by which CLSTN3 enhances SVCT2 activity (trafficking vs. stabilization) unresolved
   • In vivo relevance not tested
7. 2022 High

   Revealed a distinct adipocyte isoform, CLSTN3β, acting at ER–lipid droplet contacts to restrict droplet fusion via CIDE proteins, establishing a non-synaptic, non-neuronal cellular function.

   Evidence KO/transgenic mice, subcellular localization imaging, Co-IP with CIDE proteins, lipid-transfer assays, and cold-challenge phenotyping

   PMID:36477540

   Open questions at the time

   • Structural basis of CIDE inhibition not defined
   • Relationship between CLSTN3β and canonical synaptic CLSTN3 functions unaddressed
8. 2022 Medium

   Showed CLSTN3 overexpression in white adipose tissue impairs lipolysis and mitochondrial function via interaction with APP, linking CLSTN3 to obesity.

   Evidence AAV-mediated WAT overexpression in mice with lipolysis assays, Co-IP, and mitochondrial function assays

   PMID:35753632

   Open questions at the time

   • Single lab with limited orthogonal validation
   • Physiological relevance of the APP interaction at endogenous levels unclear
9. 2023 Medium

   Implicated hepatic CLSTN3 in lipid and glucose metabolism through an FXR-linked pathway in NAFLD models.

   Evidence AAV-mediated hepatic silencing/overexpression in HFD and db/db mice, RNAseq, and FXR-KO experiments

   PMID:37521618

   Open questions at the time

   • Direct molecular link between CLSTN3 and FXR not established
   • Partial rescue in FXR-KO indicates additional unidentified effectors
10. 2026 High

    Defined a mechanistic immune role, showing CLSTN3 dampens TLR signaling by binding DDOST and disrupting OST complex assembly to limit TLR N-glycosylation and membrane translocation.

    Evidence Genome-wide CRISPR screen with Co-IP, glycosylation assays, TLR localization assays, and macrophage inflammatory readouts under gain/loss-of-function

    PMID:41849401

    Open questions at the time

    • Whether this OST-modulating activity occurs in non-macrophage cell types not established
    • Relationship to the synaptic and adipose functions of CLSTN3 unclear

• How a single locus coordinates such distinct functions across neurons, adipocytes, hepatocytes, and macrophages, and which isoforms execute each role, remains unresolved.
• No unifying mechanistic framework linking synaptic, lipid-droplet, immune, and metabolic roles
• Isoform-specific contributions to each tissue function not systematically mapped
• No human disease mutation evidence in the corpus